Largest-ever US study on TB testing confirms benefits of IGRAs
The recent publication of the largest-ever US study comparing the use of TB blood tests (IGRAs) to the tuberculin skin test (TST) reaffirms current guidance regarding the preferred use of IGRAs for at-risk populations (1).
Including more than 20,000 participants across 10 US sites, the landmark US CDC-funded Tuberculosis Epidemiologic Studies Consortium (TBESC) study demonstrates that TB blood testing more accurately identifies latent TB among non-US-born individuals that have received the BCG vaccination, compared to TST.
Download the white paper now to learn more about this and other key findings that support the use of IGRA testing, including QuantiFERON®-TB Gold Plus, as a key tool in the global effort to end TB.
Thank you for your interest in our QIAGEN white papaer: Effectiveness of TB blood testing as a replacement for TB skin testing
Reference
* Mandatory fields
† Subject to your consent given above, QIAGEN may use your personal information for internal business and marketing purposes. The information will not be sold to any third party. QIAGEN may transfer your personal information to our CRM system (hosted by SalesForce.com, Inc. and Oracle Corp.) solely for the purposes of data hosting, phone calls and QIAGEN email distribution. You may unsubscribe at any time. Your data will be processed in compliance with applicable privacy laws including the EU General Data Protection Regulation All information you provide in this site will be governed by our Privacy Policy.